WHAT IS CLAIMED IS:

1. A method of treatment of a cancer, the method comprising the steps of

administering EC145 to a patient; and

administering to the patient one or more additional chemotherapeutic agents having a mode of action selected from the group consisting of angiogenesis inhibition, microtubule assembly inhibition, DNA cross-linking, topoisomerase inhibition, DNA intercalation, DNA synthesis inhibition, tyrosine kinase inhibition, and mitosis inhibition.

2. The method of claim 1 wherein the additional chemotherapeutic agent is selected from the group consisting of cisplatin, carboplatin, topotecan, irinotecan, bevacizumab, erlotinib, lapatinib, and pemetrexed.

3. The method of claim 2 wherein the additional chemotherapeutic agent is selected from the group consisting of carboplatin and bevacizumab.

4. The method of claim 3 wherein the additional chemotherapeutic agent is carboplatin.

5. The method of claim 3 wherein the additional chemotherapeutic agent is bevacizumab.

6. The method of claim 1 wherein the cancer is an epithelial cancer.

7. The method of claim 6 wherein the epithelial cancer is an ovarian, an endometrial, or a non-small cell lung cancer.

8. The method of claim 7 wherein the epithelial cancer is an ovarian cancer.

9. The method of claim 7 wherein the epithelial cancer is a non-small cell lung cancer.

10. The method of claim 1 wherein the additional chemotherapeutic agent is administered at a dose that is 50 to 80% of the maximum tolerated dose for the chemotherapeutic agent.

11. The method of claim 1 wherein the EC145 and the chemotherapeutic agent are administered in therapeutically effective amounts.

12. The method of claim 11 wherein the effective amounts range from about 1 $\mu g/m^2$ to about 500 mg/m^2 of body surface area.

13. The method of claim 11 wherein the effective amounts range from about 1 $\mu g/m^2$ to about 300 mg/m^2 of body surface area.

14. The method of claim 11 wherein the effective amounts range from about 10 μg/kg to about 100 μg/kg of patient body weight.

15. The method of claim 1 wherein the cancer is a platinum-resistant ovarian cancer.

16. The method of claim 1 wherein the EC145 and the additional chemotherapeutic agent are in sterile containers or packages.

17. The method of claim 1 wherein the EC145 and the additional chemotherapeutic agent have a purity of at least 90% based on weight percentage.

18. The method of claim 1 wherein the EC145 is in the form of a reconstitutable lyophilizate.

19. The method of claim 1 wherein the EC145 and the additional chemotherapeutic agent are in sterile, pyrogen-free aqueous solutions.

20. The method of claim 1 wherein the EC145 and the additional chemotherapeutic agent are administered at doses lower than their maximum tolerable doses.

21. A kit comprising EC145 and one or more additional chemotherapeutic agents having a mode of action selected from the group consisting of angiogenesis inhibition, microtubule assembly inhibition, DNA cross-linking, topoisomerase inhibition, DNA intercalation, DNA synthesis inhibition, tyrosine kinase inhibition, and mitosis inhibition.

22. The kit of claim 21 wherein the additional chemotherapeutic agent is selected from the group consisting of cisplatin, carboplatin, topotecan, irinotecan, bevacizumab, erlotinib, lapatinib, and pemetrexed.

23. The kit of claim 22 wherein the additional chemotherapeutic agent is selected from the group consisting of carboplatin and bevacizumab.

24. The kit of claim 23 wherein the additional chemotherapeutic agent is carboplatin.

25. The kit of claim 23 wherein the additional chemotherapeutic agent is bevacizumab.

26. The kit of claim 21 wherein the EC145 and the chemotherapeutic agent are in therapeutically effective amounts.

27. The kit of claim 21 wherein the EC145 and the additional chemotherapeutic agent are in sterile containers or packages.

28. The kit of claims 21 wherein the EC145 and the additional chemotherapeutic agent have a purity of at least 90% based on weight percentage.

29. The kit of claim 21 wherein the EC145 and the additional chemotherapeutic agent have a purity of at least 95% based on weight percentage.

30. The kit of claim 21 wherein the EC145 is in the form of a reconstitutable lyophilizate.

31. The kit of claim 21 wherein the EC145 and the additional chemotherapeutic agent are in sterile, pyrogen-free aqueous solutions.

AMENDED CLAIMS
received by the International Bureau on 21 May 2012 (21.05.12)

1. A method of treatment of a cancer, the method comprising the steps of administering EC145 to a patient; and

administering to the patient one or more additional chemotherapeutic agents having a mode of action selected from the group consisting of angiogenesis inhibition, microtubule assembly inhibition, DNA cross-linking, topoisomerase inhibition, DNA intercalation, DNA synthesis inhibition, tyrosine kinase inhibition, and mitosis inhibition wherein the EC145 and the additional chemotherapeutic agent are in sterile containers or packages.

2. The method of claim 1 wherein the additional chemotherapeutic agent is selected from the group consisting of cisplatin, carboplatin, topotecan, irinotecan, bevacizumab, erlotinib, lapatinib, and pemetrexed.

3. The method of claim 2 wherein the additional chemotherapeutic agent is selected from the group consisting of carboplatin and bevacizumab.

4. The method of claim 3 wherein the additional chemotherapeutic agent is carboplatin.

5. The method of claim 3 wherein the additional chemotherapeutic agent is bevacizumab.

6. The method of claim 1 wherein the cancer is an epithelial cancer.

7. The method of claim 6 wherein the epithelial cancer is an ovarian, an endometrial, or a non-small cell lung cancer.

8. The method of claim 7 wherein the epithelial cancer is an ovarian cancer.

9. The method of claim 7 wherein the epithelial cancer is a non-small cell lung cancer.

10. The method of claim 1 wherein the additional chemotherapeutic agent is administered at a dose that is 50 to 80% of the maximum tolerated dose for the chemotherapeutic agent.

11. The method of claim 1 wherein the EC145 and the chemotherapeutic agent are administered in therapeutically effective amounts.

12. The method of claim 11 wherein the effective amounts range from about 1 $\mu g/m^2$ to about 500 mg/m^2 of body surface area.

13. The method of claim 11 wherein the effective amounts range from about 1 $\mu g/m^2$ to about 300 mg/m^2 of body surface area.

14. The method of claim 11 wherein the effective amounts range from about 10 μg/kg to about 100 μg/kg of patient body weight.

15. The method of claim 1 wherein the cancer is a platinum-resistant ovarian cancer.

16. The method of claim 1 wherein the EC145 and the additional chemotherapeutic agent have a purity of at least 90% based on weight percentage.

17. The method of claim 1 wherein the EC145 is in the form of a reconstitutable lyophilizate.

18. The method of claim 1 wherein the EC145 and the additional chemotherapeutic agent are in sterile, pyrogen-free aqueous solutions.

19. The method of claim 1 wherein the EC145 and the additional chemotherapeutic agent are administered at doses lower than their maximum tolerable doses.

20. A kit comprising EC145 and one or more additional chemotherapeutic agents having a mode of action selected from the group consisting of angiogenesis inhibition, microtubule assembly inhibition, DNA cross-linking, topoisomerase inhibition, DNA intercalation, DNA synthesis inhibition, tyrosine kinase inhibition, and mitosis inhibition.

21. The kit of claim 20 wherein the additional chemotherapeutic agent is selected from the group consisting of cisplatin, carboplatin, topotecan, irinotecan, bevacizumab, erlotinib, lapatinib, and pemetrexed.

22. The kit of claim 21 wherein the additional chemotherapeutic agent is selected from the group consisting of carboplatin and bevacizumab.

23. The kit of claim 22 wherein the additional chemotherapeutic agent is carboplatin.

24. The kit of claim 22 wherein the additional chemotherapeutic agent is bevacizumab.

25. The kit of claim 20 wherein the EC145 and the chemotherapeutic agent are in therapeutically effective amounts.

26. The kit of claim 20 wherein the EC145 and the additional chemotherapeutic agent are in sterile containers or packages.

27. The kit of claims 20 wherein the EC145 and the additional chemotherapeutic agent have a purity of at least 90% based on weight percentage.

28. The kit of claim 20 wherein the EC145 and the additional chemotherapeutic agent have a purity of at least 95% based on weight percentage.

29. The kit of claim 20 wherein the EC145 is in the form of a reconstitutable lyophilizate.

30. The kit of claim 20 wherein the EC145 and the additional chemotherapeutic agent are in sterile, pyrogen-free aqueous solutions.

Claims

1. Use of EC145 in the manufacture of a medicament for the treatment of a cancer in a patient, wherein

the medicament is to be administered with one or more additional chemotherapeutic agents having a mode of action selected from the group consisting of angiogenesis inhibition, microtubule assembly inhibition, DNA cross-linking, topoisomerase inhibition, DNA intercalation, DNA synthesis inhibition, tyrosine kinase inhibition, and mitosis inhibition; and wherein the EC145 and the additional chemotherapeutic agent are in sterile containers or packages.

2. The use of claim 1 wherein the additional chemotherapeutic agent is selected from the group consisting of cisplatin, carboplatin, topotecan, irinotecan, bevacizumab, erlotinib, lapatinib, and pemetrexed.

3. The use of claim 2 wherein the additional chemotherapeutic agent is selected from the group consisting of carboplatin and bevacizumab.

4. The use of claim 3 wherein the additional chemotherapeutic agent is carboplatin.

5. The use of claim 3 wherein the additional chemotherapeutic agent is bevacizumab.

6. The use of claim 1 wherein the cancer is an epithelial cancer.

7. The use of claim 6 wherein the epithelial cancer is an ovarian, an endometrial, or a non-small cell lung cancer.

8. The use of claim 7 wherein the epithelial cancer is an ovarian cancer.

9. The use of claim 7 wherein the epithelial cancer is a non-small cell lung cancer.

10. The use of claim 1 wherein the additional chemotherapeutic agent is to be administered at a dose that is 50 to 80% of the maximum tolerated dose for the chemotherapeutic agent.

11. The use of claim 1 wherein the EC145 and the chemotherapeutic agent are to be administered in therapeutically effective amounts.

12. The use of claim 11 wherein the effective amounts range from about 1 $\mu g/m^2$ to about 500 mg/m^2 of body surface area.

13. The use of claim 11 wherein the effective amounts range from about 1 $\mu g/m^2$ to about 300 mg/m^2 of body surface area.

14. The use of claim 11 wherein the effective amounts range from about 10 $\mu g/kg$ to about 100 $\mu g/kg$ of patient body weight.

15. The use of claim 1 wherein the cancer is a platinum-resistant ovarian cancer.

16. The use of claim 1 wherein the EC145 and the additional chemotherapeutic agent have a purity of at least 90% based on weight percentage.

17. The use of claim 1 wherein the EC145 is in the form of a reconstitutable lyophilizate.

18. The use of claim 1 wherein the EC145 and the additional chemotherapeutic agent are in sterile, pyrogen-free aqueous solutions.

19. The use of claim 1 wherein the EC145 and the additional chemotherapeutic agent are to be administered at doses lower than their maximum tolerable doses.

20. A kit comprising EC 145 and one or more additional chemotherapeutic agents having a mode of action selected from the group consisting of angiogenesis inhibition, microtubule assembly inhibition, DNA cross-linking, topoisomerase inhibition, DNA intercalation, DNA synthesis inhibition, tyrosine kinase inhibition, and mitosis inhibition.

21. The kit of claim 20 wherein the additional chemotherapeutic agent is selected from the group consisting of cisplatin, carboplatin, topotecan, irinotecan, bevacizumab, erlotinib, lapatinib, and pemetrexed.

22. The kit of claim 21 wherein the additional chemotherapeutic agent is selected from the group consisting of carboplatin and bevacizumab.

23. The kit of claim 22 wherein the additional chemotherapeutic agent is carboplatin.

24. The kit of claim 22 wherein the additional chemotherapeutic agent is bevacizumab.

25. The kit of claim 20 wherein the EC145 and the chemotherapeutic agent are in therapeutically effective amounts.

26. The kit of claim 20 wherein the EC 145 and the additional chemotherapeutic agent are in sterile containers or package.

27. The kit of claims 20 wherein the EC145 and the additional chemotherapeutic agent have a purity of at least 90% based on weight percentage.

28. The kit of claim 20 wherein the EC145 and the additional chemotherapeutic agent have a purity of at least 95% based on weight percentage.

29. The kit of claim 20 wherein the EC145 is in the form of a reconstitutable lyophilizate.

30. The kit of claim 20 wherein the EC 145 and the additional chemotherapeutic agent are in sterile, pyrogen-free aqueous solutions.